Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


Investor Relations

NASDAQ : STML

$15.68 - 0.12
Volume: 141,500
Apr 17, 2014 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph
     

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline’s drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity including durable complete responses (CRs) and an overall survival (OS) benefit versus historical controls in Phase I/II studies.



Corporate Snapshot

PDF Corporate Snapshot


Corporate Presentation

PDF Corporate Presentation

View all »   RSSRecent Releases

Apr 8, 2014
Stemline Therapeutics Announces FDA Acceptance of IND for SL-701, a Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors

Apr 7, 2014
Stemline Therapeutics to Present at the 13th Annual Needham Healthcare Conference


View all »Events & Presentations

There are no upcoming events at this moment.



Copyright 2014 - Stemline Therapeutics, Inc. All rights reserved
Stemline